论文部分内容阅读
本文报道从1965年1月至1990年12月间74例经随访五年以上的子宫肉瘤的治疗效果，并就其临床相关的预后因素进行分析。全组总的五年生存率为43．2％，按五年生存率，病灶局限于子宫者为50％，超出于宜者为14．3％（P＜0．05）；广泛全宜切除者为52．9％，全宫附件切除者为607％（P＞0．05），次全宫切除者为33．3％，单纯肿瘤切除为0（P＜0．05）；几术后佐以动脉灌注化疗者，较全身或加腹腔化疗者的五年生存率高，各为73．3％和37．3％（P＞0．05）。化疗疗程不少于五疗程者较少于五疗程者高，各为84．2％和28．2％（p＞0．01）
This article reports 74 cases of uterine sarcoma who were followed up for more than five years from January 1965 to December 1990 and analyzed their clinically relevant prognostic factors. The overall five-year overall survival rate was 43.2%. According to the five-year survival rate, the lesions were localized in the uterus at 50% and beyond that at 14.3% (P <0.05) (52.9%), 607% (P> 0.05) of the total excision, 33.3% of the total hysterectomy, 0 (P <0.05) Adjuvant arterial infusion of chemotherapy, compared with systemic or intraperitoneal chemotherapy, five-year survival rates were high, each of 73.3% and 37.3% (P> 0.05). Chemotherapy course of not less than five courses were less than five courses were high, each 84.2% and 28.2% (p> 0.01)